HC Wainwright reiterated their buy rating on shares of Senseonics (NYSE:SENS – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright also issued estimates for Senseonics’ Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.14) EPS and FY2025 earnings at ($0.09) EPS.
Separately, StockNews.com initiated coverage on Senseonics in a research note on Monday, August 12th. They issued a sell rating for the company.
Get Our Latest Stock Analysis on SENS
Senseonics Stock Performance
Senseonics (NYSE:SENS – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 225.98%. The company had revenue of $4.87 million during the quarter, compared to analyst estimates of $4.86 million. As a group, sell-side analysts anticipate that Senseonics will post -0.12 EPS for the current year.
Hedge Funds Weigh In On Senseonics
A number of hedge funds have recently modified their holdings of the company. State Board of Administration of Florida Retirement System purchased a new position in shares of Senseonics during the 1st quarter valued at $91,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Senseonics by 30.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after acquiring an additional 211,128 shares during the period. Virtu Financial LLC purchased a new position in shares of Senseonics in the first quarter valued at about $162,000. Vanguard Group Inc. lifted its position in shares of Senseonics by 0.7% in the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after acquiring an additional 155,715 shares in the last quarter. Finally, RPO LLC bought a new position in shares of Senseonics in the fourth quarter worth about $37,000. 12.36% of the stock is currently owned by institutional investors.
About Senseonics
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
Further Reading
- Five stocks we like better than Senseonics
- What Investors Need to Know to Beat the Market
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How Investors Can Find the Best Cheap Dividend Stocks
- MarketBeat Week in Review – 8/12 – 8/16
- Learn Technical Analysis Skills to Master the Stock Market
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.